Vol 73, No 1 (2023)
Research paper (original)
Published online: 2023-01-20
Bone metastasis in head and neck squamous cell carcinoma – 5-year experience of an Indian Cancer Institute
1
, 1, 2, 1
, 1, 2, 1
DOI: 10.5603/NJO.a2023.0001
Nowotwory. Journal of Oncology 2023;73(1):3-9.
Abstract
Introduction. Bone metastasis (BM), a common and awful complication of advanced malignancy, is comparatively infrequent in head and neck squamous cell carcinoma (HNSCC). Having a discouraging survival of around 6-months only, BM decreases the quality of life in such patients. We reported 13 cases of BM in HNSCC patients in respect to clinical patterns, treatment modalities and outcome.
Material and methods. This is a retrospective study conducted in a tertiary cancer institute of India. Records of all HNSCC patients reviewed and patients having BM were identified.
Results. Total 13 cases of BM were found over a 5-year period; 5 patients having synchronous BM and the rest had developed metastasis later. Monostotic and polyostotic diseases were found in 8 and 5 patients, respectively, bone exclusive disease was seen in 6 patients only. Overall median survival was 6.7 months.
Conclusions. Palliation seems to be the only option once BM is diagnosed in HNSCC. All of our patients received local palliative radiation, and systemic chemotherapy to increase survival. As there is no standardized treatment for such occurrence, more case series and prospective studies are welcomed.
Keywords: bone metastasishead and neck cancermonostoticpolyostoticradiotherapy
References
- Harris AA, Hartsell WF. Palliation of bone metastases. In: Halperin EC, Wazer DE, Perez CA, Brady LW. ed. Principles and practice of radiation oncology. 7th ed. Wolters Kluwer, Philadelphia 2019: 2148–2162.
- Peters TT, Senft A, Hoekstra OS, et al. Pretreatment screening on distant metastases and head and neck cancer patients: Validation of risk factors and influence on survival. Oral Oncol. 2015; 51(3): 267–271.
- Lee DH, Kim MJ, Roh JL, et al. Distant metastases and survival prediction in head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg. 2012; 147(5): 870–875.
- Duprez F, Berwouts D, De Neve W, et al. Distant metastases in head and neck cancer. Head Neck. 2017; 39(9): 1733–1743.
- Suzuki A, Kashiwagi N, Doi H, et al. Patterns of bone metastases from head and neck squamous cell carcinoma. Auris Nasus Larynx. 2020; 47(2): 262–267.
- Bollig CA, Newberry CI, Galloway TLI, et al. Prognostic Impact of Metastatic Site and Pattern in Patients with Metastatic Head and Neck Cancer. Laryngoscope. 2021; 131(6): E1838–E1846.
- Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006; 12(20 Pt 2): 6243s–6249s.
- Errani C, Mavrogenis A, Megaloikonomos P, et al. Immunohistochemical evaluation of bone metastases. Nowotwory. Journal of Oncology. 2017; 67(1): 1–6.
- Takes RP, Rinaldo A, Silver CE, et al. Distant metastases from head and neck squamous cell carcinoma. Part I. Basic aspects. Oral Oncol. 2012; 48(9): 775–779.
- Nakanishi K, Sakai M, Sumikawa H, et al. Bone metastases from head & neck squamous cell carcinoma (HNSCC) – Reviewing the patients’ background and imaging features mainly of whole body MRI (WBMRI). Cancer Rep Rev. 2017; 1(6): 1–5.
- Samołyk-Kogaczewska N, Sierko E, Wojtukiewicz MZ. Methods of anatomical and metabolic imaging in head and neck region tumors. Nowotwory. Journal of Oncology. 2018; 68(4): 184–196.
- Al-Bulushi NK, Abouzied ME. Comparison of 18F-FDG PET/CT scan and 99mTc-MDP bone scintigraphy in detecting bone metastasis in head and neck tumors. Nucl Med Commun. 2016; 37(6): 583–588.
- Pietropaoli M, Damron T, Vermont A. Bone metastases from squamous cell carcinoma of the head and neck. J Surg Oncol. 2000; 75(2): 136–140, doi: 10.1002/1096-9098(200010)75:2<136::aid-jso11>3.0.co;2-d.
- Kuperman DI, Auethavekiat V, Adkins DR, et al. Squamous cell cancer of the head and neck with distant metastasis at presentation. Head Neck. 2011; 33(5): 714–718.
- Kotwall C, Sako K, Razack MS, et al. Metastatic patterns in squamous cell cancer of the head and neck. Am J Surg. 1987; 154(4): 439–442.
- Bhandari V, Jain RK. A retrospective study of incidence of bone metastasis in head and neck cancer. J Cancer Res Ther. 2013; 9(1): 90–93.
- Hoch S, Katabi N, Daniel H, et al. Prognostic value of level IV metastases from head and neck squamous cell carcinoma. Head Neck. 2016; 38(1): 140–146.
- Eifel PJ, Moughan J, Erickson B, et al. Patterns of radiotherapy practice for patients with carcinoma of the uterine cervix: a patterns of care study. Int J Radiat Oncol Biol Phys. 2004; 60(4): 1144–1153.
- Basu D, Siegel BA, McDonald DJ, et al. Detection of occult bone metastases from head and neck squamous cell carcinoma: impact of positron emission tomography computed tomography with fluorodeoxyglucose F 18. Arch Otolaryngol Head Neck Surg. 2007; 133(8): 801–805.
- Kim MiRa, Roh JL, Kim JS, et al. 18F-fluorodeoxyglucose-positron emission tomography and bone scintigraphy for detecting bone metastases in patients with malignancies of the upper aerodigestive tract. Oral Oncol. 2008; 44(2): 148–152.
- Grisanti S, Bianchi S, Locati LD, et al. Bone metastases from head and neck malignancies: Prognostic factors and skeletal-related events. PLoS One. 2019; 14(3): e0213934.
- Sakisuka T, Kashiwagi N, Doi H, et al. Prognostic factors for bone metastases from head and neck squamous cell carcinoma: A case series of 97 patients. Mol Clin Oncol. 2021; 15(5): 246.
- Zhang H, Zhu W, Biskup E, et al. Incidence, risk factors and prognostic characteristics of bone metastases and skeletal-related events (SREs) in breast cancer patients: A systematic review of the real world data. J Bone Oncol. 2018; 11: 38–50.
- Imura Y, Tateiwa D, Sugimoto N, et al. Prognostic factors and skeletal-related events in patients with bone metastasis from gastric cancer. Mol Clin Oncol. 2020; 13(4): 31.
- La EM, Smyth EN, Talbird SE, et al. Treatment patterns and health care resource use in patients receiving multiple lines of therapy for metastatic squamous cell carcinoma of the head and neck in the United Kingdom. Eur J Cancer Care (Engl). 2018; 27(5): e12862.
- Haigentz M, Hartl DM, Silver CE, et al. Distant metastases from head and neck squamous cell carcinoma. Part III. Treatment. Oral Oncol. 2012; 48(9): 787–793.
- Wiegand S, Zimmermann A, Wilhelm T, et al. Survival After Distant Metastasis in Head and Neck Cancer. Anticancer Res. 2015; 35(10): 5499–5502.
- Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008; 359(11): 1116–1127.
- Cho H, Nishiike S, Yamamoto Y, et al. Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma. Auris Nasus Larynx. 2015; 42(5): 396–400.
- Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001; 27(3): 165–176.
- Jin Y, An X, Cai YuC, et al. Zoledronic acid combined with chemotherapy bring survival benefits to patients with bone metastases from nasopharyngeal carcinoma. J Cancer Res Clin Oncol. 2011; 137(10): 1545–1551.
- Patel TD, Marchiano E, Chin OY, et al. Utility of Surgery/Radiotherapy in Distant Metastatic Head and Neck Squamous Cell Carcinoma: A Population-Based Approach. Otolaryngol Head Neck Surg. 2016; 154(5): 868–874.